Chardan Capital maintains Buy rating on Agenus, $40 price target

Agenus presented Phase II NEOASIS study results at ESMO 2026, showing 83% pathological response rate in dMMR colorectal cancer patients treated with neoadjuvant botensilimab plus balstilimab. 72% achieved complete response. Safety profile included Grade 1-2 immune-related adverse events in 72% of patients, with one Grade 3 colitis case. The study met its primary endpoint, supporting further evaluation.

Agenus reported 72% pathologic complete response in 18 dMMR colon cancer patients treated with botensilimab and balstilimab in a Phase 2 study. 83% achieved major pathologic response. All patients were alive at 15-month median follow-up, with 16 showing no recurrence. The study was presented at the ESMO Congress.

Agenus (AGEN) reported that 72% of patients in a phase 2 trial for locally advanced colon cancer had no detectable cancer at surgery after a six-week immunotherapy course, according to results presented at the European Society for Medical Oncology Congress.

Agenus reported Phase 2 NEOASIS trial results for dMMR colon cancer patients, showing 72% achieved a pathologic complete response and 83% a major pathologic response after six weeks of BOT+BAL treatment. The trial met its primary endpoint. Investigators plan to explore organ preservation in rectal cancer patients.

Agenus Inc. (AGEN) reported Phase 2 NEOASIS study results showing 83% of 18 patients with locally advanced dMMR colon cancer achieved a major pathologic response, with 72% having no cancer remaining at surgery after a 6-week course of botensilimab and balstilimab. Side effects were mostly mild. The company is exploring this approach in rectal cancer and MSS colon cancer.

Agenus Inc. reported Phase 2 NEOASIS study results, showing 83% MPR and 72% pCR in 18 dMMR colon cancer patients treated with botensilimab plus balstilimab. The company aims to expand use across tumors, pending further studies and regulatory discussions.